Enveda Biosciences Secures $311M Series E to Advance AI-Discovered Nature-Derived Medicines

On September 23, 2026, AI drug-discovery biotech Enveda Biosciences announced it raised $311 million in Series E financing, led by Catalio Capital Management, to advance its nature-derived medicines into later-stage clinical trials and scale its PRISM AI platform.

Enveda's Valuation Doubles Amidst Clinical Progress

The Series E financing round has valued Enveda Biosciences at $2 billion, marking a doubling of its valuation from just a year prior. This latest funding brings the company's total capital raised to over $845 million since its founding in 2019 by Viswa Colluru. New investors participating in this round include ICONIQ, Lightspeed, Durable Capital Partners, Surveyor Capital, and T. Rowe Price accounts, alongside existing investors.

Advancing AI-Discovered Drug Candidates

A primary use of the newly secured funds will be to advance Enveda's lead drug candidates, ENV-294 and ENV-308, into later-stage clinical trials. Additionally, ENV-6946 will progress through mid-phase trials. These medicines were discovered using Enveda's PRISM AI foundation model, which analyzes plants, microbes, and human biochemistry to identify potential therapeutic compounds.

In 2026, Enveda reported positive early clinical readouts for two medicines discovered by PRISM. Currently, the company has three oral medicines in human trials. One notable candidate, ENV-294, demonstrated an average 85% improvement in eczema severity after 42 days in a Phase 1b study, with no serious side effects reported.

Scaling the PRISM Platform and Automated Lab

Beyond advancing specific drug candidates, a portion of the Series E proceeds will be dedicated to scaling the PRISM platform itself and its associated automated laboratory. Since its inception in 2019, the PRISM approach has generated 17 development candidates, with three now in human trials. This continued investment aims to enhance the platform's capabilities, potentially increasing the speed and efficiency of discovering new nature-derived medicines.

The Significance of AI in Drug Discovery

Enveda's substantial funding round underscores the growing investor confidence in AI news and its application in the pharmaceutical sector. By leveraging AI to explore the vast chemical diversity found in nature, companies like Enveda aim to overcome traditional drug discovery challenges, potentially bringing novel treatments to patients more rapidly. The focus on nature-derived compounds also opens avenues for exploring therapeutic solutions from sources historically used in traditional medicine, now with the precision and speed of artificial intelligence.

Conclusion

Enveda Biosciences' $311 million Series E financing represents a significant milestone in its mission to develop nature-derived medicines using AI. With a doubled valuation and a substantial increase in total capital raised, the company is well-positioned to advance its promising drug candidates through clinical trials and further scale its innovative PRISM platform. The progress of ENV-294 and other candidates will be closely watched as Enveda continues to integrate AI into the complex process of drug discovery.

Sources

• Enveda secures $311M to bring more nature-derived AI drugs into clinical trials | TechCrunch
• Enveda raises $55M to combine ancient remedies with AI for drug discovery | TechCrunch
• Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century - Enveda
• Enveda’s $311m Series E to fund AI-driven drug discovery
• AI drug hunter Enveda raises $311M for late-stage obesity...